Geoff has served as Synthekine’s Chief Business Officer since October 2023. He is an expert in corporate strategy and business development with more than 20 years of experience in the biotechnology industry. He has worked across multiple modalities and therapeutic areas, with an emphasis on oncology, autoimmune disease, and rare disease. Prior to joining Synthekine, Geoff was Chief Business Officer at Nutcracker Therapeutics. In his previous experience, he also served as Chief Business Officer of ImmunoScape and held multiple senior executive roles at Aduro Biotech. In these positions, he worked closely with research, development, and commercial teams to strategically position the companies in the market and establish them as preferred partners for leading pharmaceutical and biotechnology organizations. Early in his career, Geoff advised pharmaceutical and biotechnology clients at McKinsey & Co., with a focus on corporate strategy, finance, due diligence, and mergers and acquisitions. Geoff holds a Ph.D. in Biochemistry and Molecular Biology from the University of California, Los Angeles and graduated with a B.S. in Chemistry from Duke University.
Copyright 2024 – Synthekine